Russell Investments Group
ACRS icon

Russell Investments Group’s Aclaris Therapeutics ACRS Stock Holding History

Russell Investments Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
308,165
+298,380
+3,049% +$1.01M ﹤0.01% 2142
2025
Q4 		$29.5K Buy
9,785
+173
+2% +$437 ﹤0.01% 3490
2025
Q3 		$18.3K Buy
9,612
+8,870
+1,195% +$15.5K ﹤0.01% 3613
2025
Q2 		$1.05K Sell
742
-1,352
-65% -$1.83K ﹤0.01% 3666
2025
Q1 		$3.2K Sell
2,094
-671
-24% -$1.43K ﹤0.01% 3438
2024
Q4 		$6.86K Hold
2,765
– – ﹤0.01% 3221
2024
Q3 		$3.18K Sell
2,765
-785
-22% -$963 ﹤0.01% 3304
2024
Q2 		$3.9K Sell
3,550
-59,222
-94% -$69.6K ﹤0.01% 3265
2024
Q1 		$77.8K Buy
62,772
+61,602
+5,265% +$73.5K ﹤0.01% 2604
2023
Q4 		$1.23K Buy
1,170
+1,137
+3,445% +$3.47K ﹤0.01% 3046
2023
Q3 		$226 Buy
+33
New +$282 ﹤0.01% 3478
2018
Q4 		– Sell
-103,185
Closed -$1.5M – 2904
2018
Q3 		$1.5M Buy
103,185
+29,645
+40% +$508K ﹤0.01% 1905
2018
Q2 		$1.47M Buy
73,540
+24,090
+49% +$445K ﹤0.01% 1924
2018
Q1 		$867K Buy
49,450
+3,421
+7% +$72.5K ﹤0.01% 2262
2017
Q4 		$1.16M Buy
46,029
+3,182
+7% +$77.5K ﹤0.01% 2081
2017
Q3 		$1.11M Buy
42,847
+1,352
+3% +$36.2K ﹤0.01% 2093
2017
Q2 		$1.13M Sell
41,495
-2,792
-6% -$75.9K ﹤0.01% 2050
2017
Q1 		$1.32M Sell
44,287
-7,837
-15% -$226K ﹤0.01% 1957
2016
Q4 		$1.41M Buy
+52,124
New +$1.33M ﹤0.01% 2003

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Russell Investments Group's ACRS Position: Q1 2026 in Review

Russell Investments Group increased its Aclaris Therapeutics (ACRS) stake by 3,049% in Q1 2026, buying an estimated $1.01M and bringing the position to 308,165 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Russell Investments Group first reported a position in ACRS in Q4 2016 and has held it in 19 quarters since. The position peaked at $1.5M in Q3 2018. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Russell Investments Group held 308,165 shares of Aclaris Therapeutics worth $1.16M as of Q1 2026.
  • Russell Investments Group bought 298,380 Aclaris Therapeutics shares in Q1 2026, an estimated $1.01M.
  • Aclaris Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2142 holding.
  • Russell Investments Group first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 19 quarters since.
  • Russell Investments Group's Aclaris Therapeutics position peaked at $1.5M in Q3 2018.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.